Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Eur J Ophthalmol ; 32(3): 1743-1750, 2022 May.
Article in English | MEDLINE | ID: mdl-34162267

ABSTRACT

PURPOSE: To report visual, clinical and radiological outcomes of three patients with fibromuscular dysplasia (FMD) that presented different ocular ischemic events, supported by different multimodal imaging. METHODS: A retrospective study including patients who attended a tertiary referral hospital from July 2016 to June 2019 referring acute visual loss and later diagnosed of FMD. Ophthalmological examination included best corrected visual acuity (BCVA), biomicroscopy, fundoscopy, fluorescein angiography (FA), and macular and retinal nerve fiber layer spectral domain optic coherence tomography (SD-OCT). Patients were admitted by the Neurology service, completing the study with blood and cerebrospinal fluid (CSF) test, serology and cultures, cerebral magnetic resonance angiography (angioMRI), and arteriography. RESULTS: Three patients were included; one male and second females. All referred unilateral acute visual loss, with BCVA of counting fingers or hand-motion. Relative afferent pupilar defect was present in all patients. Two patients associated neurological focal signs and one had chronic hypertension. Fundoscopy revealed hemorrhages and exudates in all patients, and the typical sign of "string-of-beads" in one. FA showed dye filling delay and macular and peripheral hypofluorescence. SD-OCT revealed acute and chronic retinal ischemic signs. Blood and CSF tests, serologies and cultures resulted negative. All presented cerebral vascular involvement, objectified in the cerebral angioMRI or arteriography. CONCLUSIONS: FMD should be considered in cases with unilateral sudden visual loss associated to neurological focal deficits in young patients. The typical "string-of-beads" image is rare in small arteries such as the retinal vasculature. When suspected, a complete ophthalmological examination and cerebral vascular imaging is essential to confirm the diagnosis.


Subject(s)
Fibromuscular Dysplasia , Female , Fibromuscular Dysplasia/complications , Fibromuscular Dysplasia/diagnosis , Fluorescein Angiography/methods , Humans , Male , Ophthalmoscopy , Retrospective Studies , Tomography, Optical Coherence/methods , Vision Disorders/complications , Visual Acuity
2.
Am J Cardiol ; 125(3): 409-414, 2020 02 01.
Article in English | MEDLINE | ID: mdl-31780074

ABSTRACT

Atrial fibrillation (AF) causes a substantial proportion of embolic strokes of undeterminded source (ESUS). Effective detection of subclinical AF (SCAF) has important therapeutic implications. We conducted a prospective study to determine the prevalence of SCAF in patients with ESUS through of a 21-day Holter monitoring. In an early-monitoring group, Holter was initiated immediately after hospital discharge. The results were compared with a previous cohort of patients in whom the Holter was initiated at least 1 week after hospital discharge (late-monitoring group). We included 100 patients (50 each group; 69 ± 13 years, 56% male). Mean time from ESUS to Holter was 1.2 ± 1 day in the early-monitoring group and 30 ± 15 days in the late-monitoring group. SCAF was detected in 22% of patients in the early-monitoring and 6% in the late-monitoring group (p <0.05). Patients with SCAF were older (77 ± 9 vs 67 ± 11 years, p <0.05), with a higher rate of left atrial enlargement (50% vs 20%, p<0.05), renal impairment (28% vs 5%; p<0.01), and a slower mean heart rate (55 ± 6 vs 70 ± 6 beats/min; p<0.001). On multivariate analysis, the presence of persistent bradycardia (≤60 beats/min) in the 21-day Holter was a powerful and significant risk factor for SCAF. In conclusion, the sooner 21-day Holter electrocardiogram monitoring is initiated after ESUS, the more likely SCAF can be detected. Sinus bradycardia is a powerful predictor of SCAF in patients with ESUS.


Subject(s)
Atrial Fibrillation/diagnosis , Electrocardiography, Ambulatory/methods , Intracranial Embolism/etiology , Registries , Aged , Atrial Fibrillation/complications , Female , Follow-Up Studies , Humans , Incidence , Intracranial Embolism/epidemiology , Male , Prognosis , Reproducibility of Results , Retrospective Studies , Risk Factors , Spain/epidemiology , Time Factors
3.
Head Neck ; 39(7): E77-E80, 2017 07.
Article in English | MEDLINE | ID: mdl-28474478

ABSTRACT

BACKGROUND: Cavernous sinus syndrome presents as unilateral ophthalmoplegia associated with sympathetic denervation, pain, paresthesias, and V1 and V2 distribution numbness. The etiology may be vascular, inflammatory, infectious, and, less commonly, neoplastic (metastatic). METHODS: We report a patient with incomplete cavernous sinus syndrome as the initial manifestation of previously undetected metastatic prostate adenocarcinoma. RESULTS: A 59-year-old man presented with a 2-month history of left hemicranial headaches with ptosis and binocular diplopia. Clinical evaluation found left third, fourth, and sixth cranial nerve palsy with mydriasis and ptosis. An MRI showed an enhancing lesion at the clivus with infiltration of left cavernous sinus. A trans-sphenoidal biopsy was performed, leading to diagnosis of metastatic prostate adenocarcinoma. The patient underwent treatment and achieved clinical improvement. CONCLUSIONS: In middle-aged men, it is important to include metastatic prostate adenocarcinoma in the differential diagnosis of cavernous sinus syndrome, even in the absence of primary tumor diagnosis.


Subject(s)
Adenocarcinoma/secondary , Cavernous Sinus/pathology , Chemoradiotherapy/methods , Skull Base Neoplasms/secondary , Adenocarcinoma/therapy , Biopsy, Needle , Cavernous Sinus/diagnostic imaging , Diagnosis, Differential , Diplopia/diagnosis , Diplopia/etiology , Follow-Up Studies , Headache/diagnosis , Headache/etiology , Humans , Immunohistochemistry , Magnetic Resonance Imaging/methods , Male , Middle Aged , Prostatic Neoplasms/pathology , Prostatic Neoplasms/therapy , Skull Base Neoplasms/therapy , Syndrome , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...